The first crew of all civilians is headed into orbit this month — and they are going to bring back essential research. Photo via inspiration4.com

The world's first all-civilian human spaceflight mission to orbit will be participating in health-related research projects sponsored by a Houston organization.

The crew of Inspiration4 will contribute to research projects that the Translational Research Institute for Space Health, or TRISH, at Baylor College of Medicine will sponsor. The project is a collaboration is between TRISH, SpaceX, and investigators at Weill Cornell Medicine.

"The crew of Inspiration4 is eager to use our mission to help make a better future for those who will launch in the years and decades to come," says Jared Isaacman, commander of the Inspiration4 mission, in a news release. "In all of human history, fewer than 600 humans have reached space. We are proud that our flight will help influence all those who will travel after us and look forward to seeing how this mission will help shape the beginning of a new era for space exploration."

According to the release, all biomedical data collected for the Inspiration4 mission will be accessible through an open data repository funded and overseen by TRISH. The mission will include the following TRISH-sponsored research:

  • Collect research-grade ECG activity, movement, sleep, heart rate and rhythm, blood oxygen saturation, cabin noise and light intensity.
  • Perform a series of tests in the Cognition app designed to assess changes in behavioral and cognitive performance. This is the same app that is currently used by astronauts in NASA-funded research studies.
  • Scan organ systems via a Butterfly IQ+ Ultrasound device, which is designed with artificial intelligence guidance for non-medical experts. Data collected will determine if non-medical experts can self-acquire clinical grade images without guidance from ground support and will provide a timeline of biological changes before and during spaceflight. This device is also currently being tested by astronauts on the International Space Station.
  • Collect and test drops of blood during spaceflight for markers of immune function and inflammation using a state-of-the-art miniaturized device called the Vertical Flow Immunoassay.
  • Use balance and perception tests pre-flight and immediately post-flight to measure sensorimotor adaptation during changes of gravity. These tests are currently performed by astronauts upon return from spaceflight.
  • Archive, fully analyze, and share resulting biomedical samples and data in collaboration with investigators at Weill Cornell Medicine and research data in an open format database to enable greater collaborative research.

Researchers at Weill Cornell Medicine will be collecting the environmental and biomedical data and biological samples from Inspiration4's four crew members before, during, and after the mission. These samples and data will be added to a planned Biobank that will hold cryogenically-frozen samples and data from the Inspiration4 mission. The sample collection will enable long-term research and health monitoring for astronauts. WorldQuant is providing funding support for the work at Weill Cornell Medicine.

The mission, which will be aboard SpaceX's Falcon 9, is slated for September 15 from Launch Complex 39A at NASA's Kennedy Space Center. The three-day mission will target approximately a 575 km orbit, flying farther from Earth than any human spaceflight since the Hubble Space Telescope repair missions. Inspiration4's goal is to inspire humanity and raise money for St. Jude Children's Research Hospital.

The space mission will be riding aboard SpaceX's Falcon 9. Photo via inspiration4.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”